A5011054274- Lymphoma Diagnosis and Treatment
- Drug-Induced Adverse Reactions
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Dialysis and Renal Disease Management
- CNS Lymphoma Diagnosis and Treatment
- Muscle and Compartmental Disorders
- Acute Myeloid Leukemia Research
- Cancer-related gene regulation
- CAR-T cell therapy research
Cornell University
2020
Abstract Molecular alterations in the histone methyltransferase EZH2 and antiapoptotic protein Bcl-2 frequently co-occur diffuse large B-cell lymphoma (DLBCL). Because DLBCL tumors with these characteristics are likely dependent on both oncogenes, dual targeting of is a rational therapeutic approach. We hypothesized that inhibition would be synergistic DLBCL. To test this, we evaluated inhibitor tazemetostat venetoclax cells, 3-dimensional organoids, patient-derived xenografts (PDXs). found...
Abstract Molecular alterations in the histone methyltransferase EZH2 and antiapoptotic protein BCL2 frequently co-occur diffuse large B-cell lymphoma (DLBCL). We hypothesized that inhibition would be synergistic DLBCL. To test this, we evaluated inhibitor tazemetostat venetoclax DLBCL cells, 3D organoids, patient-derived xenografts (PDXs). found are cells harbor both an mutation a BCL2/IGH translocation, as demonstrated by CI values <1 (CI: 0.034, 0.259 0.074 SUDHL-6, WSU-DLCL2,...